ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2026
Fragmented Thresholds, Unified Vision: Advancing Salivary Diagnostics for OSCC and OPMD.
Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Salivary diagnostics for oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMD) have advanced significantly, yet clinical translation remains limited. A key barrier is the lack of harmonized thresholds for candidate biomarkers, ranging from cytokines to genetic and epigenetic markers, across studies. This variability undermines biosensor calibration, impedes algorithmic integration, and restricts the scalability of AI and eHealth tools. Paradoxically, saliva is well-established in systemic disease diagnostics but remains undervalued in oral oncology. Recent initiatives, such as COST Action CA21140-INTERCEPTOR, are working to intercept oral carcinogenesis through collaborative innovation in molecular diagnostics and surveillance technologies. This letter calls for standardized protocols, multicenter validation, and digital integration to unlock saliva's full potential as a frontline diagnostic fluid. By addressing biomarker variability and embracing cross-sector collaboration, the field can move toward clinically actionable, digitally enabled solutions for early detection and monitoring of OSCC and OPMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.